Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Neuphoria Therapeutics (NEUP) over the last 4 years, with Q4 2025 value amounting to $2.1 million.

  • Neuphoria Therapeutics' Accumulated Expenses rose 32632.3% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 million, marking a year-over-year increase of 32632.3%. This contributed to the annual value of $3.0 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Neuphoria Therapeutics' Accumulated Expenses is $2.1 million, which was up 32632.3% from $3.7 million recorded in Q3 2025.
  • Neuphoria Therapeutics' 5-year Accumulated Expenses high stood at $3.7 million for Q3 2025, and its period low was $484515.0 during Q4 2024.
  • For the 4-year period, Neuphoria Therapeutics' Accumulated Expenses averaged around $1.6 million, with its median value being $1.0 million (2023).
  • In the last 5 years, Neuphoria Therapeutics' Accumulated Expenses soared by 913.96% in 2023 and then soared by 32632.3% in 2025.
  • Over the past 4 years, Neuphoria Therapeutics' Accumulated Expenses (Quarter) stood at $880579.5 in 2022, then rose by 9.14% to $961060.9 in 2023, then crashed by 49.59% to $484515.0 in 2024, then skyrocketed by 326.32% to $2.1 million in 2025.
  • Its Accumulated Expenses stands at $2.1 million for Q4 2025, versus $3.7 million for Q3 2025 and $3.0 million for Q2 2025.